Biocon Ltd 532523
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- ₹356.95
- Day Range
- ₹345.20–360.00
- 52-Week Range
- ₹217.50–395.65
- Bid/Ask
- ₹0.00 / ₹0.00
- Market Cap
- ₹414.49 Bil
- Volume/Avg
- 252,556 / 195,003
Key Statistics
- Price/Earnings (Normalized)
- 27.01
- Price/Sales
- 2.91
- Dividend Yield (Trailing)
- 0.14%
- Dividend Yield (Forward)
- 0.14%
- Total Yield
- 0.14%
Company Profile
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 9,805
- Website
- https://www.biocon.com
Comparables
Valuation
|
Metric
|
532523
|
688578
|
688266
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.01 | 22.61 | — |
Price/Book Value | 2.13 | 5.50 | 11.60 |
Price/Sales | 2.91 | 8.70 | 44.59 |
Price/Cash Flow | 15.11 | 21.46 | — |
Price/Earnings
532523
688578
688266
Financial Strength
|
Metric
|
532523
|
688578
|
688266
|
|---|---|---|---|
Quick Ratio | 0.61 | 7.39 | 2.15 |
Current Ratio | 0.99 | 7.97 | 2.31 |
Interest Coverage | 3.38 | 14,588.83 | −10.58 |
Quick Ratio
532523
688578
688266
Profitability
|
Metric
|
532523
|
688578
|
688266
|
|---|---|---|---|
Return on Assets (Normalized) | — | 24.62% | −9.86% |
Return on Equity (Normalized) | — | 26.90% | −17.41% |
Return on Invested Capital (Normalized) | — | 25.16% | −12.53% |
Return on Assets
532523
688578
688266
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rwmpzjnccc | Qxxb | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Sztqcymbb | Jndcbb | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dtypbqsmh | Fwrpdm | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pmxsqfzm | Rgzkbf | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Vlsdkmhy | Qsv | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Dxqqzmhp | Vxjq | $28.5 Bil | |||
| Moderna Inc
MRNA
| Pbwvptkj | Fxzw | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Dmfkvpzf | Lnfj | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fzbrvblg | Sdwmbg | $13.0 Bil | |||
| Incyte Corp
INCY
| Htynwld | Xnjhv | $12.9 Bil |
United States